Glucagon-like peptide 1 plays a role in glucose regulation. Sleep disturbances (obstructive sleep apnea, insufficient or poor sleep quality) have been shown to adversely affect glucose metabolism. This study aimed to explore the relationship between sleep and glucagon-like peptide 1 regulation in patients with abnormal glucose tolerance. Seventy-one adults with haemoglobin A1c levels between 5.7% and < 6.5% and no history of diabetes participated. Habitual sleep duration and efficiency were obtained from 7-day actigraphy recordings. Obstructive sleep apnea was assessed using an overnight home monitor. Glucagon-like peptide 1 levels were measured during a 75-g glucose tolerance. The area under the curve of glucagon-like peptide 1 was calculated. The mean age (SD) was 55.1 (8.3) years and median (interquartile range) haemoglobin A1c was 5.97% (5.86, 6.23). There was no relationship between sleep duration or efficiency and fasting or area under the curve glucagon-like peptide 1. Glucagon-like peptide 1 levels did not differ among those sleeping ≤ 5.75, > 5.75-< 6.5 or ≥ 6.5 h per night. Increasing apnea-hypopnea index, an indicator of obstructive sleep apnea severity, correlated with lower area under the curve glucagon-like peptide 1 (B À0.242, P = 0.045), but not with fasting glucagon-like peptide 1 (B À0.213, P = 0.079). After adjusting for sex, haemoglobin A1c and body mass index, increasing apnea-hypopnea index was negatively associated with having area under the curve glucagon-like peptide 1 in the highest quartile (odds ratio 0.581, P = 0.028, 95% CI 0.359, 0.942) . This study demonstrated that increasing obstructive sleep apnea severity was associated with lower glucagon-like peptide 1 response to glucose challenge. This could possibly be an additional mechanism by which obstructive sleep apnea affects glucose metabolism. Whether raising glucagon-like peptide 1 levels in patients with abnormal glucose tolerance with more severe obstructive sleep apnea will be beneficial should be explored.
IN TROD UCTI ON
Sleep disturbances are recognized as risk factors for abnormal glucose metabolism and obesity (Reutrakul and Van Cauter, 2014) . In experimental sleep manipulations of healthy volunteers, reduced sleep duration or sleep fragmentation resulted in a reduction of insulin sensitivity ranging from 18% to 24% without simultaneous increases in insulin levels, leading to reduced glucose tolerance and an increased risk of diabetes (Buxton et al., 2010; Nedeltcheva et al., 2009a; Spiegel et al., 1999) . In addition, sleep restriction was shown to be associated with changes in appetite regulation in favour of increased hunger and food intake, without commensurate increase in energy expenditure, placing individuals at risk for obesity (Nedeltcheva et al., 2009b (Nedeltcheva et al., , 2010 Spiegel et al., 2004; St-Onge et al., 2011) . In agreement with experimental data, epidemiological studies revealed that insufficient sleep, generally less than 5-6 h per day, and poor sleep quality were associated with an increased risk for incident diabetes and weight gain/obesity (Anothaisintawee et al., 2015; Cappuccio et al., 2008; Chaput et al., 2008; Fatima et al., 2016) . Lastly, obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent hypoxia and sleep fragmentation. Experimental intermittent hypoxia in healthy volunteers led to impaired insulin sensitivity and insulin secretion (Louis and Punjabi, 2009) . Longitudinal studies also revealed that OSA was independently associated with an increased risk of incident diabetes, independent of adiposity (Anothaisintawee et al., 2015) .
Glucagon-like peptide-1 (GLP-1) is an intestinal-derived peptide secreted from L-cells located in the distal ileum and colon in response to nutrient intake (Baggio and Drucker, 2007) . GLP-1 stimulates insulin secretion in a glucosedependent manner, inhibits glucagon secretion and delays gastric emptying, resulting in normalization of glucose excursion after meals (Baggio and Drucker, 2007) . In addition, GLP-1 promotes satiety. GLP-1 is quickly degraded by the enzyme dipeptidyl peptidase 4 (DDP-4). In individuals with impaired glucose tolerance and patients with type 2 diabetes, GLP-1 levels in response to oral glucose were found to be reduced compared with those with normal glucose tolerance (Muscelli et al., 2008; Vilsboll et al., 2001) . Obesity also impairs GLP-1 secretion independently of glucose tolerance (Hussein et al., 2014; Muscelli et al., 2008) . GLP-1 receptor agonists and DPP-4 inhibitors are widely used as anti-diabetic medications with a favourable profile on weight (Drucker and Nauck, 2006) .
Few researchers have explored whether sleep disturbances were associated with alterations in GLP-1 secretions, which could possibly lead to subsequent abnormal glucose metabolism or obesity. St-Onge et al. (2012) studied 27 normal weight healthy volunteers under two sleep conditions; short (4 h) or habitual (9 h). GLP-1 levels were observed to be lower in the afternoon after short sleep compared with habitual sleep in women only (St-Onge et al., 2012) . The authors postulated that this may lead to overeating and increased obesity risk. In another study of 12 healthy young men, total sleep deprivation resulted in a delayed postprandial GLP-1 response to breakfast compared with regular sleep (Benedict et al., 2013) . The relationship between OSA and GLP-1 was examined in a study of 96 participants without diabetes (Matsumoto et al., 2016) . Increased OSA severity was found to be associated with higher fasting GLP-1 levels and lower GLP-1 response to a meal tolerance test, although the relationship with GLP-1 response diminished after adjusting for the degree of adiposity (Matsumoto et al., 2016) . These early data suggested possible associations between sleep disturbances and GLP-1 dysregulation.
Individuals with prediabetes, estimated at 86 million people in the USA in 2012, are at risk of developing diabetes (Centers for Disease Control and Prevention, 2014) . In addition, approximately one-third of patients with diabetes are undiagnosed, especially those who are in the early stages of the disease (Centers for Disease Control and Prevention, 2014) . Stabilizing glucose control in those with early diabetes is important as the duration of glycaemic burden is a strong predictor of adverse outcomes (American Diabetes Association, 2017). To date, there have been no studies exploring the relationship between sleep disturbances in those with abnormal glucose tolerance and the regulation of GLP-1. Sleep improvement or medications targeting GLP-1 in those with sleep disturbances may be beneficial in preventing diabetes or deterioration of glucose metabolism in these individuals if such a relationship is found. Therefore, the purpose of this study was to investigate the relationship between sleep duration, sleep quality and OSA, and GLP-1 regulation in participants with abnormal glucose tolerance, including those with prediabetes and early diabetes.
MAT ERIALS AN D METH ODS
A cross-sectional study was conducted in non-shift-working adults attending the outpatient department at the Faculty of Medicine Ramathibodi Hospital with a previous diagnosis of prediabetes defined as haemoglobin A1c (HbA1c) ≥ 5.70% to < 6.50% (American Diabetes Association, 2017), and no history of elevated fasting plasma glucose (≥ 126 mg dL À1 ) or previous diagnosed diabetes (clinicaltrials.gov, NCT02229487). Fasting plasma glucose and HbA1c are convenient methods to screen for diabetes, as an oral glucose tolerance test (OGTT) is not routinely performed in clinical practice. It was expected that some of these participants would meet the criteria of diabetes diagnosis upon an OGTT (see below), hence representing early diabetes. Exclusion criteria included being currently pregnant, a history of congestive heart failure or low ejection fraction, chronic obstructive pulmonary disease, end-stage renal disease or severe chronic liver disease such as cirrhosis, stroke, permanent pacemaker placement, and use of certain medications (opioids/narcotics, alpha adrenergic blockers, clonidine, methyldopa, nitroglycerin). All participants gave written informed consent. The protocol was approved by the Institutional Review Board, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
After obtaining informed consent, weight and height were measured. Body mass index (BMI) was calculated as weight (kg)/height 2 (m) 2 . The participants then underwent the following assessments, all performed within a 2-week period.
Sleep duration and efficiency measurement
Participants wore an Actiwatch 2 wrist activity monitor (Philips Respironics, Bend, Oregon, USA) for 7 days. These monitors use highly sensitive omnidirectional accelerometers to count the number of wrist movements in 30-s epochs. The software scores each 30-s epoch as sleep or wake based on a threshold of activity counts that is estimated using activity within the epoch being scored as well as the epochs 2 min before and after that epoch. Bedtime and wake time are set by the researcher using the event markers, a sleep log data as well as an in-person review of sleep timing with the participants upon return of the watch. Sleep duration was defined as the amount of actual sleep obtained at night, and sleep efficiency (a measure of sleep quality) was defined as percentage of time in bed spent sleeping. These two variables were calculated using Actiware 6.0 software, supplied by the manufacturer. For each participant, the mean across all available nights was used. In addition, standard deviations (SD) of sleep duration and sleep efficiency were calculated to reflect the variability of these measurements. For 97% of participants in these analyses, at least 6 days of actigraphy recordings were available, and the remaining 3% had 5 days of actigraphy recordings.
Assessment of OSA
Obstructive sleep apnea was diagnosed using an FDAapproved portable diagnostic device, WatchPAT 200 (Itamar Medical, Israel), which has been validated against polysomnography (PSG) in populations with and without diabetes (Yuceege et al., 2013; Zou et al., 2006) . This noninvasive device is shaped similar to a large watch, worn on the non-dominant wrist immediately before bedtime and removed upon awakening in the morning. The device has two probes connecting to the participants' fingers to measure changes in peripheral arterial tone (PAT) and oxygen saturation, along with a built-in actigraphy to measure sleep time. The severity of OSA is assessed by PAT apnea-hypopnea index (AHI), which is automatically generated by the software, using changes in the peripheral arterial tonometry. OSA is considered present if AHI ≥ 5. OSA is considered mild if AHI ≥ 5 but < 15, moderate if AHI ≥ 15-30, and severe if AHI > 30. Because this device relies on changes in PAT, use of certain medications including alpha-blockers and short-acting nitrates, as well as a permanent pacemaker, was not allowed according to the device's operation manual. In addition, it cannot differentiate obstructive from central apnea events. Therefore, we also excluded patients with certain conditions that may pose a higher risk for central apnea. These were described in the exclusion criteria.
Glucose, HbA1c and GLP-1 measurements
After an overnight fast, 75 g glucose was given orally. Blood samples were obtained at 0 min for glucose and HbA1c, and at 0, 30, 60, 90, 120, 150 and 180 min for glucose and GLP-1 (Muscelli et al., 2008) . Glucose and HbA1c were assayed in the clinical laboratory of Ramathibodi Hospital using hexokinase enzymatic method and turbid metric inhibition immunoassay, respectively. Active GLP-1 levels were measured by enzyme-linked immunosorbent assay method (EMD Millipore, St. Charles, MO, USA). The area under the curve (AUC) of glucose and GLP-1 were calculated using the trapezoid rule.
Statistical analysis
Data are expressed as mean (SD) or median (interquartile range, IQR) or frequencies/percentages. HbA1c, AUC glucose, GLP-1, AUC GLP-1, and AHI were not normally distributed, therefore the natural logarithm (Ln) transformation of these variables was used in the analyses. To determine the factors associated with fasting GLP-1 and AUC GLP-1, Pearson correlations were used to explore the associations between demographic, glycaemic and sleep variables, and fasting GLP-1 as well as AUC GLP-1. Independent t-tests were used to compare GLP-1 levels between groups. In addition, sleep duration was categorized as ≤ 5.75 h per night, > 5.75 to < 6.5 h per night and ≥ 6.5 h per night (tertile cutoff). One-way ANOVA was used to analyse differences in fasting GLP-1 and AUC GLP-1 across sleep duration categories.
Additionally, OSA severity was explored among quartiles of AUC GLP-1. Stepwise logistic regression analysis was performed to determine an association between OSA severity and quartiles of AUC GLP-1. All analyses were performed using SPSS 18.0 (Chicago, IL, USA).
RESULTS
A total of 71 patients participated (Table 1) deviations) and fasting GLP-1 levels. Further analysis by sleep duration categories did not reveal significant differences in fasting GLP-1 levels (P = 0.593; Table 3 ). Increasing OSA severity borderline correlated with lower fasting GLP-1 (P = 0.079).
Associations between demographics, glycaemic and sleep characteristics with AUC GLP-1
The AUC GLP-1 levels were significantly higher in female compared with male participants [median (IQR) 21.20 (14.60, 33.61) versus 17.61 (8.91, 20 .59) pmol L À1 , P = 0.03]. In addition, lower BMI and lower HbA1c correlated with higher AUC GLP-1, while there was no association with age (Table 2) . Sleep efficiency, sleep duration and their variability were not associated with AUC GLP-1. Further analysis by sleep duration categories did not reveal significant differences in AUC GLP-1 (P = 0.133; Table 3 ).
There was an association between increasing severity of OSA and lower AUC GLP-1 (P = 0.045). Fig. 1a demonstrated median GLP-1 levels after 75-g glucose challenges among OSA severity groups. We therefore further explored this association by categorizing AUC GLP-1 into quartiles, with quartile 4 having the highest AUC GLP-1. There were no significant differences in OSA severity among AUC GLP-1 quartiles [median AHI (IQR) of the participants in quartile 1, 2, 3 and 4 of AUC GLP-1 were 12.7 (4.6, 23.8), 12.5 (5.6, 18.7), 9.7 (3.5, 17.5) and 6.8 (1.0, 12.3), respectively, P = 0.123]. However, the AHI of those in quartile 4 was significantly lower than that of participants in quartiles 1, 2 and 3 combined (P = 0.018; Fig. 1b ; Table 4 ). In addition, those in quartile 4 tended to be female (P = 0.06) and had higher HbA1c values than those in quartiles 1-3 (P = 0.017).
Stepwise logistic regression adjusting for sex, HbA1c, BMI, sleep duration and sleep efficiency revealed that AHI was the only variable significantly associated with being in the highest quartile of AUC GLP-1. Increasing AHI negatively associated with the chance of having AUC GLP-1 in the highest quartile (odds ratio 0.581, P = 0.027, 95% CI 0.359, 0.941).
DISCUSSION
In this study of participants with abnormal glucose tolerance, including prediabetes and early diabetes, we demonstrated that increasing severity of OSA was independently associated with a lower GLP-1 response to glucose, after adjusting for sex, BMI and glycaemic status. Habitual sleep duration and sleep quality (sleep efficiency) were not found to be related to GLP-1 levels. Lower GLP-1 response in these participants with more severe OSA could potentially lead to further abnormal glucose metabolism, weight gain and increased diabetes risk in this population. OSA has been linked to abnormal glucose metabolism through several mechanisms. In mice, intermittent hypoxia induces acute insulin resistance through activation of hepatic lipid synthesis, leading to hepatic insulin resistance, activation of sympathetic nervous system and hypothalamic pituitary axis, and alterations of adipokines (Drager et al., 2010) . In addition, intermittent hypoxia was shown to increase oxidative stress and lead to increased b-cell proliferation and cell death (Xu et al., 2009) . Our current data suggest that lower GLP-1 levels could be another potential mechanism in which OSA predisposes individuals to abnormal glucose metabolism.
Previously, there was only one study exploring the relationship between OSA severity and GLP-1 in 96 nondiabetic participants (Matsumoto et al., 2016) . In contrast to our results, it was found that increasing OSA severity was associated with higher fasting GLP-1 levels. In addition, they found that GLP-1 response to a meal tolerance test was lower with higher AHI, although the association was not significant after adjusting for waist circumference (Matsumoto et al., 2016) . The reasons for these differences could possibly be due to different studied population (non-diabetes versus prediabetes/early diabetes) and different tests utilized to evaluate GLP-1 response (meal tolerance versus glucose challenge). In addition, GLP-1 measurements were different (total GLP-1 versus active GLP-1 in our study), which could contribute to the differences in the absolute values measured, although it was suggested that the pattern of postprandial GLP-1 responses was similar between the assays (Bak et al., 2014) . In contrary to the previous studies that revealed lower afternoon GLP-1 levels after 4 days of short sleep (St-Onge et al., 2012) and a delayed postprandial GLP-1 response to breakfast after total sleep deprivation, we did not find the relationship between sleep duration and GLP-1 levels (Benedict et al., 2013) . This could be due to different sleep conditions, as we measured habitual sleep duration while others utilized experimental sleep manipulations. The timing of GLP-1 samplings also differed, as we did not assess the levels beyond 180 min after the glucose challenge. With regards to sleep quality, there was a previous suggestion of a relationship between sleep quality and GLP-1 regulation. In a study of 188 patients with type 2 diabetes, treatment with sitagliptin, a DPP-4 inhibitor, led to a significant improvement in self-reported sleep quality after 12 months (Sakamoto et al., 2013) . It was unclear if this was due to an increase in GLP-1 levels or other factors related to an improvement in glycaemic control. In this study, however, we did not find the relationship between sleep quality as measured by sleep efficiency and GLP-1 levels. The cross sectional design of our study cannot prove a causal relationship between OSA severity and GLP-1 regulation. Moreover, the mechanisms of OSA leading to reduced GLP-1 levels have not been explored, but there are possible explanations. Obesity is a strong risk factor for OSA and can influence GLP-1 levels (Muscelli et al., 2008) . Thus, obesity can be a shared phenotype. In addition, OSA can lead to insulin resistance and abnormal glucose metabolism (Pamidi et al., 2012) , which are associated with reduced GLP-1 levels (Muscelli et al., 2008) . In our study, however, OSA severity was associated with reduced GLP-1 levels after adjusting for BMI and HbA1c, suggesting that there could possibly be other mechanisms involved. It is known that GLP-1 secretion is under the control of neural regulation (Balks et al., 1997; Hansen et al., 2004) , and norepinephrine was shown to inhibit GLP-1 release (Hansen et al., 2004) . Therefore, sympathetic overactivity as a result of OSA could be a mediator in the relationship between increasing OSA severity and reduced GLP-1 levels. In addition, alterations in gut microbiota may play a role. In a mouse model of sleep apnea, 6 weeks of an exposure to intermittent hypoxia resulted in an alteration in global microbial community structure (MorenoIndias et al., 2015) . The gut microbiome is known to play a role in the host's metabolisms. For example, microbial fermentation of fibre produces short-chain fatty acids, which are shown to stimulate GLP-1 release (Tolhurst et al., 2012) . Whether changes in gut microbiota associated with sleep apnea lead to changes in GLP-1 levels have not been studied. Our results raise the questions whether continuous positive airway pressure (CPAP) treatment will result in normalization of GLP-1 levels in those with OSA and abnormal glucose tolerance. Previously, 8 h of nightly CPAP in patients with prediabetes resulted in an improved glucose tolerance and insulin sensitivity, along with a reduction in norepinephrine levels (Pamidi et al., 2015) . However, it was unknown whether the effects on glucose metabolism were partly mediated through changes in GLP-1 levels as these were not measured. Our results also raise the questions whether increasing GLP-1 levels in patients with prediabetes/early diabetes with more severe OSA could possibly be beneficial in improving glucose metabolism and weight. A few studies have explored this aspect, although none was performed specifically in the prediabetic population. Blackman et al. investigated the effect of liraglutide 3.0 mg, a GLP-1 receptor agonist, for 32 weeks in 180 obese non-diabetic individuals with moderate or severe OSA, compared with placebo. Liraglutide was associated with a significant reduction in AHI of 6.1 events per h compared with placebo, along with greater weight loss and reduction in HbA1c levels. In another study, liraglutide treatment for 3 months in 158 obese patients with type 2 diabetes, a population at high risk for OSA, led to a significant reduction in body weight, fasting glucose and excessive daytime sleepiness (Gomez-Peralta et al., 2015) . Therefore, these early data support the benefits of GLP-1 in those with OSA. Whether raising GLP-1 levels by inhibiting DPP-4 activity or using GLP-1 receptor agonist in those with prediabetes/early diabetes and OSA will prevent further deterioration of glucose metabolism should be investigated.
The current study has several strengths. To our knowledge, this is the first study to explore the relationship between OSA, sleep duration and quality, and GLP-1 levels in prediabetes/early diabetes individuals using objective sleep measurements. However, there are limitations. The number of participants is relatively small and the crosssectional design does not prove a causal relationship. OSA assessment was not performed using a standard PSG. Moreover, we did not measure glucose-dependent insulinotropic polypeptide (GIP), which is known to exert significant incretin effects, along with GLP-1 (Nauck and Meier, 2016) . However, one previous study demonstrated that higher AHI was related to lower GIP response to meal tolerance tests in patients without diabetes (Matsumoto et al., 2016) . In addition, the secretion of GLP-1 shows a rhythmic pattern that is altered by circadian disruption (Brubaker and Gil-Lozano, 2016) . It is possible that the changes in GLP-1 seen in this study could be contributed by alterations of the circadian system. However, we did not have measures of the circadian phase in this study. Lastly, only 6% of the participants had severe OSA. Therefore, the results in this study may not be generalizable to those with more severe OSA.
In summary, OSA severity, but not habitual sleep duration or quality, was associated with lower GLP-1 response to glucose challenge in patients with abnormal glucose tolerance. The mechanism underlying this association should be explored. Whether CPAP treatment will normalize GLP-1 levels, and raising GLP-1 levels in these patients with more severe OSA will possibly be beneficial in preventing further deterioration of glucose metabolism and weight control should be the subject of future research. 
